---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-032870"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:37:55.315470+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Genprex announces European Patent Office intent to grant patent for Reqorsa with PD-1 antibodies

## Summary
- European Patent Office communicated intent to grant patent for Reqorsa gene therapy combined with PD-1 antibodies for cancer.
- Existing patents already granted in US, Japan, Mexico, Russia, Australia, Chile, China, and Singapore.
- Reqorsa initially developed for lung cancer with approved drugs; shown complementary in preclinical studies.
- Company believes Reqorsa's unique attributes may improve current therapies for lung and other cancers.

## SEC filing metadata
- accession: 0001437749-25-032870
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774925032870/0001437749-25-032870-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774925032870/gnpx20251024_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-032870
- JSON: https://secwatch.observer/filing/0001437749-25-032870.json
- Plain text: https://secwatch.observer/filing/0001437749-25-032870.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.